Parkinson’s disease (PD) is a progressive neurological disorder characterized by a large number of motor and non-motor features that can impact on function to a variable degree. The syndrome of parkinsonism is highlighted, which can become apparent with akinetic rigid disorders in other brain injuries including medication-induced parkinsonism. Genetic mutations or variants, neuroimaging abnormalities and other tests are potential biomarkers that may improve diagnosis and allow the identification of persons at risk. This literature review describes pathogenesis and clinical characteristics of PD with emphasis on modern treatment and possibilities of dopamine agonists, especially pramipexole. During pramipexole treatment of the patients with the early and late stages of PD, we can observe the reduction of expression of cognitive and affective (mood) disorders, the improvement of the quality of life and social functioning.